Lesions causing refractory epilepsy, often associated with temporal lobe epilepsy (TLE), can be undetectable on standard magnetic resonance imaging (MRI) in dogs. Automated brain volumetry, widely used in human medicine, can now be applied in veterinary medicine because of the availability of brain atlases.
This study aimed to develop an automatic volumetry method, translate the outcomes into the assessment of temporal lobe volumes in dogs with idiopathic epilepsy, and correlate the results with the electroencephalography (EEG) data of epileptiform discharges (EDs).
Thirty-one dogs of various breeds with dominant temporal lobe discharge.
Retrospective, observational study. The MRI and EEG examination results of dogs referred for neurological diagnosis data between 2016 and 2021 were retrospectively analyzed. An automated volumetry method was developed, which allowed the evaluation of temporal lobe volumes of the dogs. The asymmetric ratio (AR) was then estimated, and the results were correlated with the EEG EDs.
12/31 (38%; 95% CI: 21.8%-57.8%) dogs had an asymmetric ratio >6%. Among them, reduction in temporal lobe volumes correlated with the side of the EEG EDs in 7 cases. There was no statistical correlation between temporal lobe volume changes and ED location.
Preliminary volumetric analysis of the temporal lobes indicates the presence of volume differences between the lobes in some dogs with idiopathic epilepsy. Diagnosis of TLE in dogs based on MRI volumetry in correlation with EEG examination, especially for dogs with drug-resistant epilepsy, can influence the development of new therapeutic options, such as surgery.
Dogs with internal hydrocephalus do not necessarily have high intraventricular pressure (IVP).
Not all reported MRI findings indicate high IVP and some clinical signs might be associated with elevated IVP and syringomyelia.
Fifty-three dogs.
Cross-sectional study. Clinical signs and MRI findings were evaluated for an association of IVP >12 mm Hg and syringomyelia.
High IVP was associated with obtundation OR 4.64 (95% CI 1.27-16.93) (P = .02), head tilt OR 6.42 (95% CI 1.08-37.97) (P = .04) and nystagmus OR 8.24 (95% CI 1.44-47.07) (P = .02). Pain was associated with syringomyelia OR 3.4 (95% CI 0.98-11.78) (P = .05). The number of affected ventricles was associated with high IVP OR 2.85 (95% CI 0.97-8.33) (P = .05) and syringomyelia OR 12.74 (95% CI 2.93-55.4) (P = .0007). Periventricular edema OR 24.46 (95% CI 4.54-131.77), OR 7.61 (95% CI 1.91-30.32) (P < .0002, P = .004) and signal void sign OR 17.34 (95% CI 4.01-74.95), OR 4.18 (95% CI 1.16-15.02) (P < .0001, P = .03) were associated with high IVP and syringomyelia. The probability for syringomyelia is lower with disruption of the internal capsule OR 0.19 (95% CI 0.05-0.72) (P = .01) and higher VBR OR 0.25 (95% CI 0.1-0.63) (P = .004).
Previously reported MRI findings are not predictive of high IVP. Clinical signs and MRI findings should be used to make a diagnosis of internal hydrocephalus in dogs with or without high IVP.
Esomeprazole use is increasing in dogs, but the gastrointestinal adverse events associated with q12h dosing necessitate pharmacodynamic evaluation of a reduced dose and frequency of administration.
To compare the efficacy of 2 doses of (q24h) esomeprazole in raising intragastric pH in dogs.
Nine healthy, client-owned dogs, >20 kg.
Prospective, randomized, double blinded, crossover study. Esomeprazole (0.5 or 1 mg/kg q24h) was orally administered for up to 5 days per treatment arm, and the mean percentage time intragastric pH was ≥3 (MPT3) and ≥4 (MPT4) for 24 hours periods were compared to pretreatment pH using a continuous pH monitoring system. Dogs failing to reach pH goals (MPT3 ≥75%, MPT4 ≥66%) with once daily dosing received esomeprazole 1 mg/kg PO q12h to determine if a higher dose would improve acid suppression.
No significant difference in the MPT3 or MPT4 was identified between treatments for any time point (P > .05). Both doses increased the MPT pH ≥3 and 4 median [range] (0.5 mg/kg, 1 mg/kg) on days 1 (MPT3: 76.8% [44-100], 69.2% [28.2-100]; MPT4: 65.6% [16.7-99.3], 54.9% [14.9-93.3]; P = .0009) and 2 (MPT3:77.2% [27.4-100], 75.4% [49.4-89.5]; MPT4: 66.3% [15.5-100], 59.7% [33.8-81.2]; P = .0005) of PPI treatment compared to pretreatment (MPT3: 58.3% [0.02-93.9], 52.6% [6.1-94.7]; MPT4: 25.2% [0-86.8], 32.4% [1.8-89.3]). Six dogs (66%, [0.36, 0.97]) reached pH goals established in humans with q24h dosing.
Both q24h PO esomeprazole doses were effective in raising intragastric pH, despite high intersubject variability, but 33% of dogs required q12h dosing to reach pH goals.
Primary glomerular disease resulting in protein-losing nephropathy (PLN) is an uncommon cause of chronic kidney disease in cats, yet is important to recognize because it warrants specific treatment that impacts outcome.
Characterize clinicopathologic findings, prognostic indicators, and short- (≤30 days) and long-term survival of cats with PLN.
Thirty-seven cats with naturally occurring PLN.
Medical records of cats with PLN admitted to a veterinary teaching hospital were retrospectively reviewed.
Median age was 3 years (range, 1.5-11.5 years) and 17/37 (46%) were males. Short-term survival was 57%. The estimated median survival time of all cats was 424 days (95% confidence interval [CI], 0-1098 days). Common clinical signs included lethargy (57%), edema (46%) and weight loss (35%). Edema was more common in short-term survivors compared with nonsurvivors (odds ratio [OR], 0.21; 95% CI, 0.05-0.86-20.4; P = .04). Serum creatinine concentration at presentation was negatively associated with long-term survival (OR, 1.3; 95% CI, 1.03-1.52; P = .01). Administration of immunosuppressive and antiproteinuric medications was more common among short-term survivors compared with nonsurvivors (18/20 [90%] vs 9/16 [56%]; OR, 7.0; 95% CI, 1.2-40.8; P = .05 and 17/20 [85%] vs 7/16 [44%]; OR, 7.3; 95% CI, 1.5-35.2; P = .01, respectively). Partial or complete remission was documented in 11/31 (36%) cats and was associated with both short (OR, 3.3; 95% CI, 1.7-6.5; P < .001) and long-term survival (P = .003).
Cats with PLN have a guarded prognosis, but achieving remission improves outcome. Cats presented with edema rather than azotemia are more likely to respond to treatment.
A 7-year-old male castrated Cavalier King Charles Spaniel was hospitalized for 12 days for treatment of severe congestive heart failure secondary to myxomatous mitral valve disease. During that time, 6 serum samples from different days were analyzed for serum biochemical and renin-angiotensin-aldosterone system components. Serum chloride concentrations (ranging from 71.6 to 103.1 mmol/L) were inversely related to angiotensin I concentrations, aldosterone concentrations, a surrogate marker of renin activity, and a surrogate marker of adrenal responsiveness to angiotensin II. In light of recent studies showing that hypochloremia is associated with advanced heart failure in dogs and is associated with poor outcomes in people, the information from the dog in this report supports exploration of RAAS dysregulation as an underlying mechanism.
Workload associated with the high frequency Colombian Paso Fino gait has not been evaluated.
To determine the oxygen consumption (V̇O2), heart rate (HR), stride frequency: breathing ratio, and hematology associated with the Paso Fino gait, including whether exercise-induced pulmonary hemorrhage (EIPH) occurs.
Eleven Paso Fino horses.
Prospective cohort study. Horses performed a standardized Paso Fino gait test across a wooden sounding board, simulating competition. V̇O2 and ventilatory parameters (tidal volume [VT]; peak inspiratory and expiratory airflows [PkV̇I, PkV̇E]; respiratory rate [RR], minute ventilation [V̇E]) were measured using a portable ergospirometry facemask. Heart rate was measured using electrocardiograms. Post-exercise lactate, hematocrit, bicarbonate, pH, electrolytes, and biochemistry concentrations were measured. EIPH was assessed via tracheobronchoscopy. Four horses completed a secondary high-intensity gallop to elicit peak V̇O2 for comparative purposes.
Median [IQR] mean individual HR during the Paso Fino gait was 190 [178, 201] bpm. Relative V̇O2 measured 49.8 [48.4, 59.5] mL/(kg min; VT = 8.6 [8.0, 10.7] L; RR = 87.1 [75.4, 99.5] bpm; V̇E = 869 [740, 902] L/min; PkV̇I = 33.4 [32.7, 37.2] L/s; PkV̇E = 44.2 [40.3, 46.0] L/s). Horses took 2.8 [2.7, 2.9] strides/second and had a stride frequency: breathing ratio of 2.0 [1.8, 2.3]. Post-exercise blood lactate concentration and hematocrit measured 2.7 mmol/L and 50% respectively. Three horses showed endoscopic evidence of Grade-1 EIPH. The Paso Fino gait V̇O2 and HR equaled 79% V̇O2pk and 91% maximal HR, respectively, based on the high-intensity gallop.
The Paso Fino gait represents submaximal exercise based on V̇O2 < V̇O2pk and blood lactate.
Periparturient reproductive complications appear to be common in hospitalized goats. More information is needed about periparturient reproductive complications and survival in goats with these conditions.
Identify exposure factors associated with nonsurvival in periparturient does hospitalized ≤1 day or ≥2 days.
A total of 198 periparturient does presented to 9 university veterinary hospitals from October 2021 to June 2022.
Multicenter, matched case-control study. Conditional logistic regression was used to identify exposure factors associated with nonsurvival in periparturient does hospitalized ≤1 day or ≥2 days.
Overall doe survival was 79% (156/198). Survival in the 1st day of hospitalization was 71% (52/73) and survival in does hospitalized ≥2 days was 83% (104/125). Among goats hospitalized ≤1 day, labor duration before admission (odds ratio [OR] = 4.8; P = .04), uterine tears (OR = 48.2; P < .001), and vaginal/perineal trauma diagnosed during hospitalization (OR = 6.2; P = .03) were associated with nonsurvival. Among goats hospitalized ≥2 days, factors associated with nonsurvival included labor duration before admission (OR = 6.2; P = .004), pregnancy toxemia (OR = 6.07; P = .04), and Cesarean section (OR = 11.35; P = .02).
Longer labor duration before admission is an important predictor of nonsurvival in hospitalized does. Clients should be educated that early detection and veterinary care are critical for improving outcome in periparturient does.
Oxidative stress is a potential contributor to chronic kidney disease (CKD) progression but has not been evaluated in dogs and cats with CKD.
Oxidative stress is higher in animals with CKD compared with healthy controls and decreases with the advancing CKD stage. The aim of this study was to determine the presence and intensity of oxidative stress in dogs and cats at different CKD stages.
Sixty dogs and 30 cats with naturally acquired CKD; 10 dogs and 14 cats, healthy controls.
Analytical cross-sectional study. Oxidative stress was evaluated by measuring the urinary concentration of F2-isoprostane (uF2-IsoPs) normalized to urinary creatinine.
Urinary F2-isoprostanes normalized to urinary creatinine of healthy dogs and of dogs with CKD Stages 1 to 4 was 3.3 ng/mg, 4.7 ng/mg (range, 1.0-73.4), 2.4 ng/mg (range, 0.4-7.8), 0.52 ng/mg (range, 0.01-2.9), and 0.37 ng/mg (range, 0.01-0.6), respectively. Urinary F2-isoprostanes differed among CKD stages (P < .001), but not compared with controls. uF2-IsoPs of healthy cats and cats with CKD Stages 1 to 4 was 0.68 ng/mg (range, 0.2-1.4), 0.97 ng/mg (range, 0.4-1.8), 0.6 ng/mg (range, 0.002-2.0), 0.94 ng/mg (range, 0.3-2.3), and 0.2 ng/mg (range, 0.01-0.4). Urinary F2-isoprostanes differed among stages (P = .05) but not compared with healthy controls.
Oxidative stress might be present in dogs and cats with CKD. Its magnitude declines as the disease progresses, therefore, it should be considered a potential therapeutic target mostly at the early stages of the disease.
Selected research communications of the
34th Symposium of the ESVN-ECVN
23rd-24th September 2022
The European College of Veterinary Neurology (ECVN) Symposium and the Journal of Veterinary Internal Medicine (JVIM) are not responsible for the content or dosage recommendations in the abstracts. The abstracts are not peer reviewed before publication. The opinions expressed in the abstracts are those of the author(s) and may not represent the views or position of the ECVN. The authors are solely responsible for the content of the abstracts.
TIMETABLE OF THE SYMPOSIUM
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：